Clinical Trial Update: A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of a fixed-dose combination tablet containing GSK587323 has been completed in adults with hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• GSK587323

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension | Phase 1 | Status: COMPLETED